Olmesartan: 360-degree Perspectives Befitting an Angiotensin Receptor Blocker.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Association of Physicians of India Country of Publication: India NLM ID: 7505585 Publication Model: Print Cited Medium: Print ISSN: 0004-5772 (Print) Linking ISSN: 00045772 NLM ISO Abbreviation: J Assoc Physicians India Subsets: MEDLINE
    • Publication Information:
      Publication: Bombay : Association of Physicians of India
      Original Publication: Bombay [1953?]-
    • Subject Terms:
      Tetrazoles*/therapeutic use ; Hypertension*/drug therapy ; Imidazoles*/therapeutic use ; Angiotensin II Type 1 Receptor Blockers*/therapeutic use; Humans ; Antihypertensive Agents/therapeutic use ; Blood Pressure/drug effects
    • Abstract:
      India has a high burden of hypertension (HTN), which is often poorly controlled, leading to hypertension-mediated organ damage (HMOD). In the management of HTN, angiotensin receptor blockers (ARBs) assume prime importance, being first-line agents for most patient subgroups. Olmesartan is a highly efficacious ARB that demonstrates sustained blood pressure (BP) reduction over 24 hours. Moreover, it also assumes a protective role by reducing microvascular inflammation, left ventricular hypertrophy, proteinuria, vascular stiffness, central aortic BP, cardiocerebrovascular events and atrial fibrillation. To enhance therapeutic compliance and achieve BP goals, single-pill combinations with other antihypertensive agents are also available. This review holistically summarizes the evidence of olmesartan for HTN management for not only BP reduction but also organoprotective effects.
      (© Journal of The Association of Physicians of India 2024.)
    • Accession Number:
      8W1IQP3U10 (olmesartan)
      0 (Tetrazoles)
      0 (Imidazoles)
      0 (Angiotensin II Type 1 Receptor Blockers)
      0 (Antihypertensive Agents)
    • Publication Date:
      Date Created: 20241215 Date Completed: 20241215 Latest Revision: 20241215
    • Publication Date:
      20241216
    • Accession Number:
      10.59556/japi.72.0780
    • Accession Number:
      39676196